MetabolomicsWorkbenchapplication/xmlhttp://www.metabolomicsworkbench.org/rest/study/study_id/ST000743/mwtabprimaryOK2000000Maureen KachmanMass SpectrometryESIDiabeteshttp://www.metabolomicsworkbench.org/data/DRCCMetadata.php?Mode=Study&StudyID=ST000743Gender:male | Glycemic status:pre-diabetic | Neuropathy:NeuropathyGender:male | Glycemic status:pre-diabetic | Neuropathy:no neuropathyGender:male | Glycemic status:diabetic | Neuropathy:no neuropathyGender:female | Glycemic status:diabetic | Neuropathy:no neuropathyGender:female | Glycemic status:normoglycemic | Neuropathy:NeuropathyGender:female | Glycemic status:normoglycemic | Neuropathy:no neuropathyGender:male | Glycemic status:diabetic | Neuropathy:NeuropathyGender:female | Glycemic status:diabetic | Neuropathy:Neuropathymkachman@med.umich.eduReversed phase POSITIVE ION MODE. Reversed phase NEGATIVE ION MODE. C18 NEGATIVE ION MODE. C18 POSITIVE ION MODE.MetabolomicsWorkbenchMetabolomicsHumanHomo SapiensBiomedical Research Core Facilities, University of MichiganN-ACETYL-L-PHENYLALANINE (M+NA)+TG 52:7; [M+NH4]+@9.61N-(docosanoyl)-sphing-4-enine; [M-H]-@8.46SALICYLATE #2 (M-H)-RAFFINOSE (M+NA)+TG 53:1; [M+NH4]+@10.92SM 41:2; [M+Na]+@7.62FFA(18:0)1-METHYLXANTHINE (M-H)-SM 40:2; [M]+@7.20PC 34:5; [M+H]+@5.16SUCROSE (M+CL)-SM 42:2; [M]+@7.64GLYCOCHENODEOXYCHOLIC ACID (M+H)+[-H2O]INOSINE (M+H)+CYSTEIC ACID (M+H)+DIPALMITOYL PHOSPHATIDYLETHANOLAMINE (M-H)-TG 48:0; [M+NH4]+@10.51PC 30:1; [M+H]+@5.4716:0-18:0 PC (M+CL)-CE(18:2); [M+NH4]+@10.73TG 49:0; [M+NH4]+@10.65TG 60:5; [M+NH4]+@10.98SM 43:2; [M]+@7.97PE 33:2; [M-H]-@6.06FFA(18:1)lysoPE 20:3; [M-H]-@1.63GLUCOSE (M+CL)-TG 58:7; [M+NH4]+@10.40VALINE (M+NA)+L-TRYPTOPHAN-15N2 [ISTD] (M-H)-lysoPC 22:6; [M+H]+@1.27SM 39:1; [M]+@7.34plasmenyl-PC 38:3; [M+Na]+@7.08TG 62:13; [M+NH4]+@9.89TG 56:4; [M+NH4]+@10.71CerP 32:1; [M-H]-@5.13THYROXINE (M-H)-5-HYDROXY OMEPRAZOLE (M-H)-ASPARAGINE (M+H)+MG 18:1; [M+NH4]+@2.95TG 56:10; [M+NH4]+@9.66URIDINE (M-H)-plasmenyl-PE 34:3; [M-H]-@6.33ARACHIDONIC ACID (M-H)-BIS(2-ETHYLHEXYL)PHTHALIC ACID (M+H)+PE 35:4; [M-H]-@6.06plasmenyl-PE 36:5; [M-H]-@6.28KYNURENIC ACID (M+H)+PC 37:4; [M-Ac-H]-@6.53MG 18:0; [M+NH4]+@3.49DG 30:2; [M+NH4]+@6.42OLEIC ACID (M+H)+PE 36:6; [M-H]-@5.61TG 50:2; [M+NH4]+@10.30HOMOGENTISIC ACID (M+H)+SM 30:0; [M]+@4.65C12 GALACTOSYL(BETA) CERAMIDE (D18:1/12:0) (M+NA)+ZEATIN [ISTD] (M+H)+lysoPE 22:5; [M-H]-@1.54CE(22:4); [M+NH4]+@10.803-HYDROXY-3-METHYLGLUTARIC ACID (M-H)-CARNOSINE (M+NA)+TETRADECADIENOYLCARNITINE (*) M+SUBERIC ACID (M+NA)+2-DEOXY-D-GLUCOSE (M+CL)-CHOLINE PHOSPHATE (M+H)+PHENYLALANINE (M-H)-PC 40:9; [M-Ac-H]-@5.38TG 52:6; [M+NH4]+@9.80TG 50:5; [M+NH4]+@9.71TG 54:4; [M+NH4]+@10.42CL 78:5; [M-2H](2-)@6.45TG 56:1; [M+NH4]+@11.27TG 60:9; [M+NH4]+@10.34GLYCEROL MYRISTATE (M+NA)+DG 32:1; [M+NH4]+@7.45LINOLEOYLCARNITINE (*) (M+H)+PE 40:6; [M-H]-@6.89INDOLE-3-ACETIC ACID (M+H)+CAFFEINE (M+H)+GUANINE (M+H)+TG 60:8; [M+NH4]+@10.52PC 32:1; [M+H]+@6.06CITRIC ACID (M-H)-EPIBRASSINOLIDE [ISTD] (M+NA)+TG 54:7; [M+NH4]+@9.88PC 30:3; [M+H]+@5.27TG 60:13; [M+NH4]+@9.69PI 34:2; [M-H]-@5.28N-ACETYLGLYCINE (M+NA)+CITRAMALIC ACID (M-H)-1-METHYLADENOSINE (M+CL)-lysoPE 22:6; [M-H]-@1.3016:0 LYSO PC (M+H)+PC 37:5; [M-Ac-H]-@6.06TG 60:10; [M+NH4]+@10.18CE(18:0); [M+NH4]+@11.27DG 34:4; [M+NH4]+@6.86METHIONINE (M+H)+CORTISOL (M+CL)-plasmenyl-PE 40:5; [M-H]-@7.37CALCIDIOL (M+H)+[-H2O]TG 48:3; [M+NH4]+@9.83DEHYDROEPIANDROSTERONE SULFATE (M-H)-PE 38:6; [M-H]-@6.12TG 52:1; [M+NH4]+@10.78FFA(16:0)TG 52:5; [M+NH4]+@9.99SM 36:1; [M]+@6.43CHOLIC ACID (M-H)-EICOSANOYLCARNITINE (*) (M+H)+PC 37:1; [M+H]+@7.62TG 46:3; [M+NH4]+@9.56PE 32:1; [M-H]-@6.24PC 30:2; [M-Ac-H]-@4.92METHYL JASMONATE (M+NA)+PE 40:5; [M-H]-@7.12SALICYLURIC ACID (M+NA)+PC 33:1; [M-Ac-H]-@6.46plasmenyl-PE 32:1; [M-H]-@6.58TG 55:1; [M+NH4]+@11.15DG 35:1; [M+NH4]+@8.17DG 35:2; [M+NH4]+@7.823-HYDROXYLAUROYLCARNITINE (*) (M+H)+CE(22:5); [M+NH4]+@10.64PI 40:5; [M-H]-@5.99N-ACETYL-DL-SERINE (M+H)+[-H2O]lysoPC 20:4; [M+H]+@1.37ADENOSINE 5'-MONOPHOSPHATE (M+H)+SM 37:1; [M]+@6.77plasmenyl-PE 38:6; [M-H]-@6.52PC 33:2; [M-Ac-H]-@6.00CHOLESTEROL (M+H)+[-H2O]lysoPE 20:4; [M-H]-@1.34HIPPURIC ACID (M+NA)+CL 82:15; [M-2H](2-)@5.911-METHYLADENOSINE (M+H)+TG 48:1; [M+NH4]+@10.28PE 36:5; [M-H]-@5.96PC 42:1; [M+H]+@9.00S-ADENOSYL-L-HOMOCYSTEINE (M-H)-TG 52:4; [M+NH4]+@10.16URIDINE (M+H)+3-METHOXYTYROSINE (M+H)+4-ACETAMINOPHEN SULFATE (M+H)+PANTOTHENIC ACID (M+NA)+TG 56:2; [M+NH4]+@11.06PC 39:4; [M+H]+@6.87HYODEOXYCHOLIC ACID (M-H)-PC 39:3; [M+H]+@7.32TG 58:8; [M+NH4]+@10.26TG 51:4; [M+NH4]+@10.10OCTENOYLCARNITINE (*) M+DEOXYURIDINE (M+NA)+OLEIC ACID (M-H)-DG 40:0; [M+NH4]+@9.52lysoPE 18:2; [M-H]-@1.37TG 56:3; [M+NH4]+@10.86TG 53:2; [M+NH4]+@10.73TG 60:11; [M+NH4]+@10.07PC 37:2; [M-Ac-H]-@7.24CE(18:3); [M+NH4]+@10.44plasmenyl-PE 42:6; [M-H]-@7.75ZEATIN [ISTD] (M-H)-lysoPC 22:4; [M+H]+@1.77TG 56:0; [M+NH4]+@11.50lysoPC 16:1; [M+H]+@1.22ISOCITRIC ACID (M-H)-PC 36:5; [M-Ac-H]-@5.70P-ACETAMIDOPHENYL BETA-D-GLUCURONIDE (M+NA)+BILIVERDIN (M+H)+plasmenyl-PE 36:4; [M-H]-@6.65L-[15N]ANTHRANILIC ACID [ISTD] (M-H)-PE 32:0; [M-H]-@6.75SM 32:0; [M]+@5.44GLYCOCHENODEOXYCHOLIC ACID (M+H)+PE 36:4; [M-H]-@6.22BIS(2-ETHYLHEXYL)PHTHALIC ACID (M+NA)+OLEIC ACID (M+NA)+N-(hexadecanoyl)-sphing-4-enine; [M-H]-@6.841-METHYLXANTHINE (M+H)+CL 74:7; [M-2H](2-)@6.09ACETAMINOPHEN (TN TYLENOL) (M-H)-PC 36:6; [M+H]+@5.58PI 36:4; [M-H]-@5.28PG 34:2; [M-H]-@5.50STEAROYLCARNITINE (*) (M+H)+THEOPHYLLINE (M+H)+DG 34:5; [M+NH4]+@6.39KYNURENINE (M+NA)+TG 55:3; [M+NH4]+@10.75N-(octadecanoyl)-sphing-4-enine; [M-H]-@7.44PC 42:2; [M+H]+@8.61URIDINE (M+CL)-TG 54:1; [M+NH4]+@11.04L-TRYPTOPHAN-15N2 [ISTD] (M+H)+HIPPURIC ACID (M+H)+SM 33:0; [M]+@5.78TG 52:2; [M+NH4]+@10.5516:0 LYSO PC (M+NA)+PC 40:10; [M+H]+@5.63PC 34:2; [M+H]+@6.22TG 49:3; [M+NH4]+@10.03TG 54:8; [M+NH4]+@9.69lysoPC 22:5; [M+H]+@1.50PC 42:4; [M+H]+@7.99SM 30:1; [M+Na]+@4.37PC 35:2; [M-Ac-H]-@6.58PC 33:3; [M+H]+@5.51XANTHINE (M-H)-SM 36:2; [M]+@6.02DG 30:1; [M+NH4]+@6.871-METHYLURIC ACID (M-H)-IBUPROFEN (M+NA)+SM 32:1; [M]+@5.09lysoPC 20:5; [M+H]+@1.03ALPHA-TOCOPHEROL (M+H)+PI 34:1; [M-H]-@5.74plasmenyl-PE 42:5; [M-H]-@7.88plasmenyl-PE 36:2; [M-H]-@7.33LINOLEIC ACID (M-H)-DOCOSAHEXAENOIC ACID (M-H)-PANTOTHENIC ACID (M+H)+plasmenyl-PE 36:3; [M-H]-@6.90TG 46:1; [M+NH4]+@10.03TG 44:2; [M+NH4]+@9.50PE 36:3; [M-H]-@6.54lysoPC 18:1; [M+H]+@1.78CE(17:1); [M+NH4]+@10.78P-ACETAMIDOPHENYL BETA-D-GLUCURONIDE (M-H)-EICOSADIENOYLCARNITINE (*) (M+H)+TG 50:4; [M+NH4]+@9.93PE 38:1; [M-H]-@7.35CerP 34:2; [M-H]-@5.34L-HISTIDINE (M+H)+lysoPC 18:0; [M+H]+@2.41plasmenyl-PE 38:2; [M-H]-@7.83SM 33:1; [M]+@5.48PC 42:8; [M+H]+@6.32CE(16:0); [M+NH4]+@10.91MYRISTOLEIC ACID (M-H)-lysoPC 19:0; [M+H]+@2.87TG 58:5; [M+NH4]+@10.77OMEPRAZOLE (M+H)+ADIPIC ACID (M+H)+PC 40:6; [M-Ac-H]-@6.69GLUCOSE (2M+NA)+DG 33:0; [M+NH4]+@8.13plasmenyl-PE 40:6; [M-H]-@7.17PC 38:5; [M+H]+@6.33INDOLE-3-ACETIC ACID (M+NA)+PC 32:3; [M-Ac-H]-@5.18PC 42:9; [M+H]+@5.98PE 40:8; [M-H]-@5.99FFA(24:2)PA 34:2; [M-H]-@6.28DECANOYLCARNITINE (*) (M+H)+SM 34:1; [M]+@5.75PE 37:2; [M-H]-@6.453-(4-HYDROXYPHENYL)LACTIC ACID (M+NA)+DG 35:3; [M+NH4]+@7.403-(4-HYDROXYPHENYL)LACTIC ACID (M-H)-DG 33:1; [M+NH4]+@7.67DG 32:2; [M+NH4]+@7.01TG 57:8; [M+NH4]+@10.19TG 60:7; [M+NH4]+@10.67DG 38:4; [M+NH4]+@7.87KYNURENINE (M+H)+PALMITOLEIC ACID (M-H)-ELAIDIC ACID (M+H)+GLUCOSE (M+NA)+TG 58:2; [M+NH4]+@11.29PIPECOLIC ACID (M+H)+GLYCOCHOLIC ACID (M-H)-5'-METHYLTHIOADENOSINE (M+H)+plasmenyl-PE 32:0; [M+H]+@7.093-METHYL-2-OXOPENTANOIC ACID (M-H)-SUCCINIC ACID (M-H)-lysoPC 17:1; [M+H]+@1.41DG 30:0; [M+NH4]+@7.34TG 55:6; [M+NH4]+@10.24PE 40:7; [M-H]-@6.38CYSTATHIONINE (M+H)+TG 51:2; [M+NH4]+@10.50plasmenyl-PE 38:1; [M-H]-@8.25CE(20:4); [M+NH4]+@10.49PE 38:2; [M-H]-@6.86XANTHOSINE (M-H)-PE 33:0; [M+H]+@7.00PG 36:1; [M-H]-@6.44TG 53:4; [M+NH4]+@10.33DEPHOSPHO-COA (M+H)+TG 60:12; [M+NH4]+@9.85FFA(24:3)18:0 LYSO-PE (M+H)+PC 42:10; [M-Ac-H]-@5.75TG 48:2; [M+NH4]+@10.06SULFADIMETHOXINE (M-H)-SM 35:2; [M]+@5.55PALMITOLEYLCARNITINE (*) M+CITRIC ACID (M+NA)+DG 36:1; [M+NH4]+@8.43SALICYLURIC ACID (M-H)-PI 36:1; [M-H]-@6.34ACETAMINOPHEN (TN TYLENOL) (M+H)+plasmenyl-PE 38:3; [M-H]-@7.53plasmenyl-PC 36:4; [M+Na]+@6.574-HYDROXYPHENYLACETIC ACID (M+H)+TRYPTOPHAN (M+NA)+PC 39:7; [M+H]+@5.96GLYCOCHOLIC ACID (M+H)+[-H2O]FFA(24:0)PC 29:0; [M+H]+@5.61THEOPHYLLINE (M-H)-PC 40:4; [M-Ac-H]-@7.33PALMITIC ACID (M-H)-TG 52:3; [M+NH4]+@10.36TYROSINE (M-H)-lysoPE 18:0; [M-H]-@2.44PIMELIC ACID (M+NA)+TG 51:5; [M+NH4]+@9.872-HYDROXY-3-METHYLBUTYRIC ACID (M-H)-DECENOYLCARNITINE (*) (M+H)+BUTYRYLCARNITINE (*) (M+H)+FFA(20:4) Arachidonic acidPE 36:2; [M-H]-@6.99SM 39:2; [M]+@6.99TAUROLITHOCHOLIC ACID (M+H)+LEUKOTRIENE B4 (M+H)+PE 37:3; [M-H]-@6.92PI 38:4; [M-H]-@5.88HIPPURIC ACID (M-H)-TG 42:0; [M+NH4]+@9.732-HYDROXY-3-METHYLBUTYRIC ACID (M+NA)+plasmenyl-PE 36:1; [M-H]-@7.73lysoPC 16:0; [M+H]+@1.62PI 38:3; [M-H]-@6.13FFA(24:1)PC 34:3; [M-Ac-H]-@5.81PG 36:2; [M-H]-@5.97XANTHOSINE (M+H)+LYSINE (M+NA)+SM 42:1; [M]+@8.21PC 42:3; [M+H]+@8.06TG 54:6; [M+NH4]+@10.07MALIC ACID (M-H)-4-METHYL-2-OXOPENTANOIC ACID (M-H)-TG 56:6; [M+NH4]+@10.34lysoPC 20:0; [M+H]+@3.30DEOXYURIDINE (M+CL)-TG 50:0; [M+NH4]+@10.77TG 53:3; [M+NH4]+@10.53SM 44:1; [M]+@8.76OLEOYL-GLYCEROL (M+NA)+PC 39:0; [M+Na]+@8.23PC 35:3; [M-Ac-H]-@6.12DG 40:8; [M+NH4]+@7.12ZEATIN [ISTD] (M+CL)-DG 40:6; [M+NH4]+@7.64ISO-BUTYRYLCARNITINE (*) (M+H)+ISOLEUCINE (M+H)+DESLORATADINE (M+H)+CE(22:6); [M+NH4]+@10.43TRYPTOPHAN (M+H)+DG 40:7; [M+NH4]+@7.49TETRADECENOYLCARNITINE (*) M+TG 42:1; [M+NH4]+@9.47PE 36:1; [M-H]-@7.44SM 37:2; [M]+@6.39TG 53:0; [M+NH4]+@11.13P-ACETAMIDOPHENYL BETA-D-GLUCURONIDE (M+H)+PI 36:2; [M-H]-@5.95TG 42:2; [M+NH4]+@9.21SM 34:2; [M]+@5.24EPIBRASSINOLIDE [ISTD] (M+CL)-SM 43:1; [M]+@8.462-HYDROXYBUTYRIC ACID (M-H)-TG 40:0; [M+NH4]+@9.41TG 51:3; [M+NH4]+@10.30PC 42:5; [M+H]+@7.57PC 34:1; [M+H]+@6.65OCTANOYLCARNITINE (*) (M+H)+TG 53:7; [M+NH4]+@9.74PC 36:2; [M+H]+@6.84plasmenyl-PC 44:4; [M+Na]+@8.40ADIPIC ACID (M-H)-CerP 34:1; [M-H]-@5.84METHYLMALONIC ACID (M-H)-TG 50:3; [M+NH4]+@10.10plasmenyl-PC 18:0; [M+Na]+@1.81PE 35:2; [M-H]-@6.68DG 36:3; [M+NH4]+@7.64TG 54:3; [M+NH4]+@10.62DEOXYCHOLIC ACID (M+CL)-16:0 LYSO PC (M+CL)-MYRISTOYLCARNITINE (*) (M+H)+lysoPC 20:1; [M+H]+@2.56GLYCOCHENODEOXYCHOLIC ACID (M+NA)+PC 38:2; [M-Ac-H]-@7.51DG 40:5; [M+NH4]+@8.04TRYPTOPHAN (M-H)-FFA(22:2)SM 38:2; [M]+@6.41DG 34:0; [M+NH4]+@8.38PC 41:6; [M+H]+@6.96TG 53:6; [M+NH4]+@9.96PE 34:1; [M-H]-@6.86lysoPE 16:0; [M-H]-@1.65OLEOYLCARNITINE (*) (M+H)+TG 54:2; [M+NH4]+@10.83lysoPC 18:2; [M+H]+@1.37INDOLE-3-ACETALDEHYDE (M+H)+SPHINGOSINE (M+H)+DEOXYCHOLIC ACID (M-H)-3-HYDROXYBENZALDEHYDE (M+H)+[-H2O]DEOXYADENOSINE (M+CL)-IBUPROFEN CARBOXYLIC ACID (M-H)-PC 39:6; [M-Ac-H]-@6.46PE 37:4; [M-H]-@6.65PC 36:1; [M+H]+@7.29TG 57:6; [M+NH4]+@10.5218:0 LYSO-PE (M-H)-IBUPROFEN (M-H)-FFA(22:3)NERVONIC ACID (M-H)-SM 38:0; [M]+@5.82PG 36:0; [M-H]-@6.9024:0 SM (D18:1/24:0) (M+NA)+PI 38:5; [M-H]-@5.35SALICYLURIC ACID (M+H)+PALMITOYLCARNITINE (M+H)+DG 34:3; [M+NH4]+@7.14PHENYLPYRUVIC ACID (M-H)-INOSINE (M+NA)+PC 38:6; [M+H]+@6.13SM 29:1; [M]+@3.96PG 38:4; [M-H]-@6.09PE 38:4; [M+H]+@7.01PANTOTHENIC ACID (M-H)-TYROSINE (M+H)+DG 36:0; [M+NH4]+@8.83TG 56:5; [M+NH4]+@10.53SM 40:1; [M]+@7.682-METHYLMALEIC ACID (M-H)-MG 17:0; [M+Li]+@3.18lysoPC 22:0; [M+H]+@4.26CAFFEINE (M+NA)+TG 44:1; [M+NH4]+@9.76FFA(22:0)PC 38:3; [M+H]+@7.07CIS-11-EICOSENOIC ACID (M-H)-PC 44:5; [M+H]+@8.08N-CYCLOHEXYLFORMAMIDE (M+H)+PC 40:2; [M+H]+@8.03DODECENOYLCARNITINE (*) M+PE 38:3; [M-H]-@6.4916:0-18:0 PC (M+H)+DG 36:2; [M+NH4]+@8.06THEOPHYLLINE (M+NA)+DG 38:5; [M+NH4]+@7.573-METHYLXANTHINE (M-H)-PA 34:1; [M-H]-@6.72PC 38:4; [M+H]+@6.85TG 54:0; [M+NH4]+@11.25TG 49:2; [M+NH4]+@10.23URIC ACID (M+H)+PE 39:6; [M-H]-@6.56ADIPIC ACID (M+NA)+N-(15Z-tetracosenoyl)-sphing-4-enine; [M-H]-@8.47FFA(22:1)DG 38:2; [M+NH4]+@8.52VALINE (M+H)+TG 57:3; [M+NH4]+@11.01ACETYLCARNITINE (M+H)+P-ACETAMIDOPHENYL BETA-D-GLUCURONIDE (2M+H)+PC 28:1; [M+H]+@4.65PE 38:7; [M-H]-@5.81TG 56:9; [M+NH4]+@9.82GALACTURONIC ACID (M+NA)+[-H2O]PE 33:1; [M-H]-@6.53NICOTINAMIDE (M+H)+4-PYRIDOXIC ACID (M-H)-plasmenyl-PE 40:4; [M-H]-@7.76MYRISTIC ACID (M-H)-PC 40:5; [M-Ac-H]-@7.06LAUROYLCARNITINE (M+H)+PG 32:0; [M-H]-@5.80lysoPC 26:0; [M+H]+@5.96SULFADIMETHOXINE (M+NA)+TG 58:12; [M+NH4]+@9.60DODECENOYLCARNITINE (*) II M+ORNITHINE (M+H)+DG 34:2; [M+NH4]+@7.52STEARIC ACID (M-H)-PC 39:8; [M+H]+@6.04N-ACETYLNEURAMINIC ACID (M+H)+CORTISONE (M+CL)-TG 56:8; [M+NH4]+@9.96PC 44:4; [M+H]+@8.56TG 58:11; [M+NH4]+@9.75PC 38:7; [M+H]+@5.53lysoPC 24:1; [M+H]+@4.31SM 40:5; [M]+@5.96PG 33:1; [M-H]-@6.55plasmenyl-PE 34:1; [M-H]-@7.16PC 28:0; [M-Ac-H]-@5.28PROPIONYLCARNITINE (*) (M+H)+SPERMINE (M+H)+DG 36:5; [M+NH4]+@6.97PC 36:4; [M+H]+@6.10PE 37:6; [M-H]-@5.97URIC ACID (M-H)-ISOVALERYLCARNITINE (*) (M+H)+SN-GLYCERO-3-PHOSPHOCHOLINE (M+H)+SM 31:1; [M]+@4.75PG 33:0; [M-H]-@6.0925-HYDROXYCHOLESTEROL (M+H)+[-H2O]PE 34:2; [M-H]-@6.42CL 72:5; [M-2H](2-)@6.24SM 38:4; [M]+@5.75SULFADIMETHOXINE (M+H)+PC 41:5; [M+H]+@7.28lysoPC 20:2; [M+H]+@1.93PI 36:3; [M-H]-@5.41CREATINE (M+H)+DG 38:1; [M+NH4]+@8.58TG 58:6; [M+NH4]+@10.57plasmenyl-PE 34:0; [M-H]-@7.23FFA(20:2)CL 74:5; [M-2H](2-)@6.551-METHYLURIC ACID (2M-H)-GALACTARIC ACID (M-H)-TG 49:1; [M+NH4]+@10.47TRANS-ACONITIC ACID (M-H)-PC 40:8; [M-Ac-H]-@5.80ALPHA-LINOLENIC ACID (M+NA)+URIDINE (M+NA)+PC 30:0; [M+Na]+@6.00SM 35:0; [M]+@6.46TG 46:0; [M+NH4]+@10.27CORTISOL 21-ACETIC ACID (M+NA)+lysoPC 15:0; [M+H]+@1.25PE 34:3; [M-H]-@5.95SM 34:0; [M+Na]+@6.02PC 42:7; [M+H]+@7.50EPIBRASSINOLIDE [ISTD] (M+H)+PC 42:11; [M+H]+@5.78SM 33:2; [M]+@4.98N-(octadecanoyl)-sphinganine; [M-H]-@7.61N-ACETYL-L-ALANINE (M-H)-lysoPE 17:0; [M-H]-@2.05CE(20:5); [M+NH4]+@10.33PG 36:3; [M-H]-@5.33AZELAIC ACID (M-H)-PC 40:7; [M+H]+@6.87TG 55:7; [M+NH4]+@10.07OXALOACETIC ACID (M-H)-[-H2O]plasmenyl-PE 34:2; [M-H]-@6.71PC 38:9; [M+H]+@5.48PC 42:6; [M+H]+@7.15PE 36:0; [M-H]-@7.86PC 35:5; [M+H]+@5.64RIBITOL (M+CL)-SPERMIDINE (M+H)+TG 58:10; [M+NH4]+@9.89lysoPC 24:0; [M+H]+@5.14TG 58:4; [M+NH4]+@10.91PI 40:6; [M-H]-@5.84PC 37:6; [M-Ac-H]-@5.80CYTIDINE 5'-DIPHOSPHOCHOLINE (M+K)+HOMOVANILLIC ACID (M+H)+PE 38:5; [M-H]-@6.51SM 32:2; [M]+@4.63PC 39:5; [M-Ac-H]-@6.66TG 58:3; [M+NH4]+@11.09CARNITINE (M+H)+CE(18:1); [M+NH4]+@10.86CE(20:3); [M+NH4]+@10.71lysoPC 20:3; [M+H]+@1.53TG 53:5; [M+NH4]+@10.14FFA(20:0)PC 35:1; [M-Ac-H]-@7.09PC 40:1; [M+H]+@8.47TG 51:1; [M+NH4]+@10.71DG 31:1; [M+NH4]+@7.15TG 56:7; [M+NH4]+@10.21SM 42:5; [M]+@6.54EICOSENOYLCARNITINE (*) (M+H)+24:0 SM (D18:1/24:0) (M+CL)-DG 36:4; [M+NH4]+@7.31TG 40:1; [M+NH4]+@9.11GLUCONIC ACID (M-H)-SM 44:2; [M]+@8.26N-ACETYL-D-GLUCOSAMINE (M+CL)-3-METHYLXANTHINE (M+H)+TRYPTOPHAN (2M-H)-DESMOSTEROL (M+H)+[-H2O]SPHINGANINE (M+H)+TG 58:1; [M+NH4]+@11.52PA 36:4; [M-H]-@6.24PE 35:1; [M-H]-@7.12lysoPC 14:0; [M+H]+@1.07plasmenyl-PE 38:5; [M-H]-@6.74FFA(20:1)PC 37:3; [M-Ac-H]-@6.77plasmenyl-PE 40:3; [M-H]-@8.06PC 36:3; [M+H]+@6.41TG 46:2; [M+NH4]+@9.79PE 37:5; [M-H]-@6.19SM 41:1; [M+Na]+@8.03TG 58:9; [M+NH4]+@10.11RIBOFLAVIN (M+H)+PC 35:4; [M-Ac-H]-@5.94CE(16:1); [M+NH4]+@10.62FFA(18:2)ACETAMINOPHEN (TN TYLENOL) (M+NA)+HYPOXANTHINE (M+H)+PS 38:4; [M-H]-@6.00PE 40:3; [M-H]-@7.12TG 54:5; [M+NH4]+@10.20lysoPC 18:3; [M+H]+@1.101-AMINOCYCLOPROPANE-1-CARBOXYLIC ACID (M+H)+N-(tetracosanoyl)-sphing-4-enine; [M-H]-@8.92TG 52:0; [M+NH4]+@11.03DEOXYCHOLIC ACID (2M-H)-HEXANOYLCARNITINE (*) M+TYROSINE (M+NA)+SM 38:1; [M]+@7.13plasmenyl-PE 38:4; [M-H]-@7.24LYSINE (M+H)+PC 32:0; [M+H]+@6.58PYRUVIC ACID (M-H)-THEOBROMINE (M+H)+lysoPE 18:1; [M-H]-@1.83PC 32:2; [M-Ac-H]-@5.61PC 34:4; [M-Ac-H]-@5.54TG 50:1; [M+NH4]+@10.53DG 32:0; [M+NH4]+@7.88DG 38:6; [M+NH4]+@7.22PE 40:4; [M-H]-@7.42CREATININE (M+H)+Weight Reductions, PRE, CPD photolyase activity, Weight Reduction, human being, PhrB photolyase activity, female human body, Males, deoxyribonucleic cyclobutane dipyrimidine photolyase activity, Metabonomic, Lipidomes, "Neuropathy" EXACT [SNOMEDCT_2005_07_31:277878001], Metabonomics, Loss of weight, photoreactivating enzyme activity, pigmented retinal epithelium, pigmented epithelium, Client, female, deoxyribodipyrimidine photolyase activity, stratum pigmentosum retinae, peripheral nerve disorder, stratum pigmentosum (retina), MODIFIER OF SNC1, retinal pigment, Weight, Weight Losses, deoxyribonucleic photolyase activity, dipyrimidine photolyase (photosensitive), Losses, 3, stratum pigmentosa retinae, NUP96, outer pigmented layer of retina, Reductions, (2Z)-but-2-enedioate, Metabolomic, NOS" EXACT [SNOMEDCT_2005_07_31:42658009], neuropathy, epithelium, "Neuropathy" EXACT [MTH:NOCODE], retinal pigment layer, male, MOS3, RPE, deoxyribocyclobutadipyrimidine pyrimidine-lyase activity, "Neuropathy" EXACT [SNOMEDCT_2005_07_31:193167000], PRECOCIOUS, "Neuropathy, maleate, photolyase activity, retinal pigmented epithelium, peripheral neuropathy, Reduction, pigmented retina, F23A5.3, "Neuropathy (disorder)" EXACT [SNOMEDCT_2005_07_31:264554005], man, retinal pigment epithelium, human, DNA cyclobutane dipyrimidine photolyase activity, SUPPRESSOR OF AUXIN RESISTANCE 3, p. pigmentosa retinae, male human body, phr A photolyase activity, Lipidome, pigment epithelium of retina, Loss, DNA-photoreactivating enzyme, Patient, Clients, Lipidomic., pigmented retina epithelium, deoxyribonucleate pyrimidine dimer lyase (photosensitive), "Neuropathy" EXACT [SNOMEDCT_2005_07_31:277317008], "Neuropathy (disorder)" EXACT [SNOMEDCT_2005_07_31:386033004], Females, F23A5_3backward, C18, D1, PTHB1, reversed, B1, B1.Metabonomic, Weight Reductions, Reduction, Losses, Weight Reduction, Metabonomics, Loss, Metabolomic, Reductions, Loss of weight, Weight Losses., Weight0.00.00.00.00.00falseMetabolomics of bariatric weight lossHuman patients were enrolled in a bariatric weight loss clinic and followed. Patients were male and female, normoglycemic,pre-diabetic and diabetic and with and without neuropathy. One 500 ul aliquot will be submitted for both untargeted metabolomics and shotgun lipidomics.Mon Jun 19 00:00:00 BST 2017ST0007439606